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Abstract 
Background: This study aims to assess the effect of radiation treatment on the tumour vasculature and its down‑
stream effects on hypoxia and choline metabolism using a multimodal approach in the murine prostate tumour 
model CWR22. Functional parameters derived from Positron Emission Tomography (PET)/Computer Tomography 
(CT) with 18F‑Fluoromisonidazole (18F‑FMISO) and 18F‑Fluorocholine (18F‑FCH) as well as Dynamic Contrast‑Enhanced 
Ultrasound (DCE‑US) were employed to determine the relationship between metabolic parameters and microvascular 
parameters that reflect the tumour microenvironment. Immunohistochemical analysis was employed for validation.
Methods: PET/CT and DCE‑US were acquired pre‑ and post‑treatment, at day 0 and day 3, respectively. At day 1, 
radiation treatment was delivered as a single fraction of 10 Gy. Two experimental groups were tested for treatment 
response with 18F‑FMISO and 18F‑FCH.
Results: The maximum Standardized Uptake Values (SUVmax) and the mean SUV (SUVmean) for the 18F‑FMISO group 
were decreased after treatment, and the SUVmean of the tumour‑to‑muscle ratio was correlated to microvessel den‑
sity (MVD) at day 3. The kurtosis of the amplitude of the contrast uptake A was significantly decreased for the control 
tumours in the 18F‑FCH group. Furthermore, the eliminating rate constant of the contrast agent from the plasma kel 
derived from DCE‑US was negatively correlated to the SUVmean of tumour‑to‑muscle ratio, necrosis and MVD.
Conclusions: The present study suggests that the multimodal approach using 18F‑FMISO PET/CT and DCE‑US seems 
reliable in the assessment of both microvasculature and necrosis as validated by histology. Thus, it has valuable diag‑
nostic and prognostic potential for early non‑invasive evaluation of radiotherapy.
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Background
Positron Emission Tomography (PET), which is a func-
tional imaging technique, can differentiate between 
cancer and normal tissues due to differences in the phe-
notype. The most common approach is based on abnor-
mal metabolic patterns such as glucose metabolism [1]. 
Fluorine-18-fluorodeoxyglucose (18F-FDG) provides a 
measure of enhanced glucose metabolism by entering the 
normal glycolytic pathway, but it is accumulated since 
the 2′-hydroxyl group halts complete catabolism. There-
fore, the tracer accumulates at sites of enhanced glyco-
lytic activity. This also means that 18F-FDG has limited 
efficacy for visualizing low-risk prostate cancer due to 
its low glycolytic activity [2]. However, 18F-FDG may be 
useful in patients with hormone-resistant poorly differ-
entiated cell types [3], since androgen has a modulatory 
effect on the glucose metabolism of androgen-dependent 
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tumours [4]. Therefore, alternative radiotracers are cur-
rently being investigated such as 18Fluorine-Fluorom-
isonidazole (18F-FMISO) which is sensitive to hypoxia 
[5] and 18F-Fluorocholine (18F-FCH) whose uptake and 
metabolism are growth related [6]. Both 18F-FMISO 
and 18F-FCH represent phenotype traits recognised as 
hallmarks of malignancy [7, 8]. 18F-FMISO is a nitromi-
dazole, an electron acceptor that under hypoxic condi-
tions will be reduced to an alkylating agent and retained 
in cells inversely related to O2 concentration [9]. It was 
chosen for its promising capabilities for predicting radio-
therapy response [6]. 18F-FCH is synthesized into the cell 
membrane in the form of phosphatidylcholine, the pri-
mary phospholipid of cell membranes and is a potential 
marker of cell division [3, 6]. Choline uptake is known to 
be increased in lung, colorectal, and prostate cancer due 
to elevated choline kinase activity in these tissues [7]. 
Under aerobic conditions, androgen-sensitive tumours 
have shown higher uptake of choline than for 18F-FDG 
[4]. Furthermore, 11C-Choline PET in combination to 
Diffusion-Weighted Magnetic Resonance Imaging (DW-
MRI) has significant correlations with the Gleason Score 
used to classify the malignance of prostatic cancers [10]. 
Nevertheless, the clinical value of 18F-FCH is still contro-
versial regarding the detection of a malignant focus in the 
prostate as well as local tumour extent (T-staging) [3].
The relatively short half-life of these radiotracers 
requires on-site or near-site production that is not always 
available. However, despite accessibility challenges, PET 
and specific PET-tracers in clinical use have the advan-
tage of better sensitivity above other methods used rou-
tinely to detect cancer and cancer metastasis [11]. MRI 
and Ultrasound (US) provide better spatial resolution 
than PET, and are more widely available, cheaper, sim-
pler to use and utilizes non-ionizing radiation. In addi-
tion to morphology, functional information is achieved 
using a dynamic acquisition with suitable contrast agents, 
i.e., dynamic contrast-enhanced MRI (DCE-MRI) and US 
(DCE-US).
Ideally, a multimodal approach is preferable, but the 
scant availability of integrated systems, makes such 
implementation difficult [12]. Therefore, a detailed inves-
tigation and comparison of the methods under the same 
conditions is mandatory to define suitable and reliable 
imaging biomarkers. The present study aims to assess the 
effect of radiation treatment on multimodal functional 
parameters using 18F-FMISO PET/CT and 18F-FCH PET/
CT as biomarkers for hypoxia and proliferation, respec-
tively, as well as DCE-US. Furthermore, to determine in 
a combined approach the relationship between meta-
bolic parameters and microvascular parameters charac-
terizing the tumour microenvironment. The results of 
PET/CT and DCE-US were validated by comparing to 
immunohistochemical parameters such as microvessel 
density and necrosis.
Methods
Animals
This study was approved by the Norwegian Animal 
Research Authority (Oslo, Norway) and is in agreement 
with the European Convention for the Protection of Ver-
tebrate Animals used for experiments and other scientific 
purposes (ETS 123). Experiments were carried out in 
accordance with the approved protocols.
Healthy male, sexually mature Hsd:Athymic Nude-
Foxn1nu mice (6 weeks old, 21–28 g), purchased at Har-
lan Laboratories (The Netherlands), were used in this 
study. The mice were hosted under specific pathogen-free 
conditions at constant temperature and humidity, before 
and during the experiment. Sterilized food and water 
were provided ad libitum.
Approximately (2  ×  2  ×  2) mm3 tissue from the 
CWR22 human androgen-sensitive xenograft was sub-
cutaneously implanted according to procedures previ-
ously reported [13]. Tumours were implanted bilaterally 
so each mouse could be used as control and treated 
simultaneously. The mice were included in the experi-
ment when their shortest tumour diameter reached 
8 mm (the same calliper was used which provided a min-
imum measurement of 0.1  mm). Nevertheless, not all 
the mice developed both tumours, and not both tumours 
reached a suitable size to be included in the experiment. 
The available tumours were randomly distributed by 
simple randomization according to the tracer to be used 
in PET (n18F-FMISO = 14 + n18F-FCH = 14), as well as into 
control and treated mice. Treated and untreated control 
mice were euthanized at day 3. Subsequently, the tumour 
tissue was excised. The distribution of mice per day and 
modality are specified in Table 1.
Radiation treatment
At day 1, the animals were anesthetized and transported 
to the Department of Oncology and Medical Physics at 
Haukeland University Hospital for radiation treatment. 
Injectable anaesthesia was administered subcutaneously 
using a dose of 0.1 ml/body weight (BW) of a mixture of 
ketamine hydrochloride (75 mg/kg Ketalar®, Pfizer, Nor-
way), medetomidine hydrochloride (0.1 mg/kg Domitor® 
vet, Orion Pharma AS, Norway), and saline.
All treated mice were positioned within the radiation 
field minimizing the exposure to vital organs and con-
trol tumours. Subsequently, a Varian Clinac 600C linear 
accelerator (6 MV x-rays) was used to deliver a single 
dose of 10  Gy. During the irradiation, the control mice 
were located outside the treatment vault at approximately 
5 m away from the source, except when bilateral tumours 
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were irradiated. In such cases the non-irradiated tumours 
were positioned as far as possible of the irradiation field.
Contrast agent and radioactive tracers
18F (half-life 109.8  min) was locally produced using 
PETrace 6 (GE, Lund, Sweden). 18F-FMISO and 18F-FCH 
were produced using GE Tracerlab MX with reagent kits 
from ABX (ABX GmbH, Radeberg, Germany).
Micromarker (Fujifilm Visualsonics, Toronto, Canada) 
microbubbles were used as contrast agent for DCE-US 
whose mean diameter ranges from 2.3–2.9 µm [14].
Imaging acquisition and quantification
PET/CT scans were performed using the integrated 
PET-CT scanner nanoScan PC PET∙CT (Mediso Medi-
cal Imaging Systems Ltd, Budapest, Hungary). The PET 
field of view (FOV) was 9.5 × 8 cm in axial and transaxial 
directions respectively, allowing whole-body imaging of 
mice. The PET detectors consist of LYSO crystals, and 
acquisition was performed in 1:5 coincidence and nor-
mal count mode. PET images were reconstructed using 
the supplier’s reconstruction algorithm Tera-Tomo 
3D (OSEM), with corrections for depth-of-interaction 
(DOI), radionuclide decay, randoms, crystal dead time, 
detector normalization, and attenuation correction, and 
with a detector coincidence mode of 1:3, 4 iterations 
and 6 subsets, and no filtering. CT images were recon-
structed using the RamLak filter. The PET and CT images 
were co-registered automatically. Images were recon-
structed with a voxel size of 0.25 × 0.25 × 0.25 mm3 for 
CT, and 0.4 ×  0.4 ×  0.4  mm3 for PET. PET image data 
analyses were performed using InterView Fusion version 
2.02.055.2010 (Mediso Ldt., Budapest, Hungary).
18F-FMISO and 18F-FCH PET/CT were acquired pre- 
(day 0) and post-treatment (day 3). The mice were anes-
thetized with sevoflurane (Sevoflo, Abbott, Illinois, USA), 
in 50  % O2 and 50  % air (induction 4  %, maintenance 
1.5–2 %). The tracers were injected through the tail vein 
using a 30G (12 mm) insulin needle connected to a 26G 
(20 mm) catheter tube (BD Vasculon Plus IV, Medinor). 
Respiratory rate and body temperature were monitored 
continuously during the image acquisitions and kept at a 
constant level.
A 120 min interval between tracer injection and the 
start of the scan was used for 18F-FMISO. The DCE-
US acquisition was performed immediately before 
the PET/CT acquisition, following the protocols 
previously described [15]. In the 18F-FCH group, a 
30 min interval was used between injection and start 
of the PET/CT scan. In all cases, the length of the 
PET/CT scan was 30  min. The SUV were calculated 
for each tumour as well as on muscle tissue, where 
SUV  =  CPET(T)/(ID/BW), being CPET(T) the meas-
ured activity in tissue, ID the injected dose measured 
in kBq, and BW the mouse body weight in kg. The 
whole tumour was included in the region of interest 
(ROI) to allow further analysis of tumour heterogene-
ity and variance in uptake.
DCE-US quantification was performed by in-house 
developed software using Matlab R2011b (MathWorks, 
Inc, Natick, MA, USA) as previously described [15]. 
Shortly, a region of interest (ROI) was delineated around 
the entire tumour using the ultrasound images excluding 
surrounding skin, connective and necrotic tissue. Signal 
intensities were converted into relative signal intensity 
(RSI) and fitted to the Brix model [16] using the Lev-
enberg–Marquardt least-squares minimization. Voxel-
wise estimates of the microvascular parameters kep, kel, 
and A were provided. Furthermore, the median curve 
associated to the ROI was also fitted to the Brix model 
providing an additional estimation of the microvascular 
parameters per tumour.
In this model, kep is the exchange rate constant from 
the extracellular extravascular space (EES) to plasma; kel 
is the eliminating rate constant of the contrast agent from 
the plasma; A is the amplitude of the contrast uptake. 
Akep obtained as the product of A and kep, reflects perme-
ability surface area per unit volume of vasculature [17].
No constraints were applied to the parameters in 
the fitting process but no negative values were allowed. 
Unfitted voxels were set to zero and included in the 
calculations.
Table 1 Distribution of mice per day and modality
n refers to the number of animals used, while C and T correspond to the control and the treated group, respectively
C control, T treated
18F-FMISO GROUP 18F-FCH GROUP
DCE-US PET/CT Histology DCE-US PET/CT Histology
Day 0 n = 13
6 (C)/7 (T)
n = 13
6 (C)/7 (T)
– n = 14
8 (C)/6 (T)
n = 9
4 (C)/5 (T)
–
Day 3 n = 14
7 (C)/7 (T)
n = 13
6 (C)/7 (T)
n = 13
6 (C)/7 (T)
n = 14
9 (C)/5 (T)
n = 9
4 (C)/5 (T)
n = 14
8 (C)/6 (T)
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Immunohistochemistry
Treated and untreated control tumours were taken for 
immunohistochemistry on day 3. The immunohisto-
chemical preparation of the samples and subsequent 
analysis of the specimens were performed following the 
protocols described in detail previously [15]. The tumour 
vascularity was quantified by both in-house software 
developed in Matlab 2014b and manually by a blinded 
investigator. For the manual quantification, microvessel 
count (MVD) of CD-31 positive structures per 0.5 mm2 
was assessed in six randomly selected regions. The per-
centage of necrosis per sample was determined using 
ImageJ 1.48v (NIH, Bethesda, MD, USA) assessed as the 
ratio of the number of non-stained DAPI (4′,6-diamid-
ino-2-phenylindole) regions with low autofluorescence 
signal to the total number of pixels per sampling area.
Statistical analysis
Statistical analysis was performed in R [18] using in-
house developed software. PET parameters, including 
SUVmean (the average value of the SUV in the whole 
tumour ROI) and SUVmax (single voxel value) in the 
tumour and muscle, tumour-to-muscle ratio, homo-
geneity, entropy and intensity variation, were grouped 
by imaging day: day 0 and day 3, as well as by group: 
treated and untreated control. Histograms for the 
microvascular parameters derived from DCE-US were 
grouped similarly to PET. Mean, median, first and third 
quartile, as well as skewness and kurtosis were used 
for the statistical analysis. Similarly, the median curve 
analysis and the derived median values of the microvas-
cular parameters were tested. The Wilcoxon’s matched-
pairs test was used to determine intergroup differences 
at day 0 and day 3 and to assess intragroup differences 
from day 0 to day 3. If significant, the provided approxi-
mation to the Z value is reported. Kendall’s Tau-b test 
was employed to assess correlation between parameters 
derived from PET and DCE-US for each experimental 
group (18F-FMISO and 18F-FCH), as well as correlation 
to histological parameters (MVD and necrosis) derived 
from the manual and the automatic quantification. The 
correlation analysis employed the mean value of each 
parameter per tumour according to Table  1. The Bon-
ferroni adjustment method was employed as correction 
for multiple testing. A significance level of 5 % was con-
sidered in all tests.
Results
Volume changes
Tumour volumes were estimated by the same experi-
enced investigator according to calliper measurements 
as well as DCE-US and PET/CT images. No signifi-
cant intragroup changes were found longitudinally 
for any of the experimental groups (18F-FMISO and 
18F-FCH). Similarly, no significant intergroup dif-
ferences for tumour volumes were detected between 
treated and control mice at any imaging day.
Longitudinal changes
18F‑FMISO PET/CT
Figure  1 displays the maximum intensity projection 
(MIP) for a mouse imaged using 18F-FMISO. At 2  h 
post-injection, 18F-FMISO particularly accumulates in 
the centre of the tumour due to a hypoxic tumour core. 
When including all the tumours in the experiment at day 
0, significantly decreased SUVmax (Z = 2.7, p < 0.01) and 
SUVmean (Z  =  1.9, p  =  0.05) were detected from day 
0 to day 3 in the treated group. The SUVmax declined 
from 1.68  ±  0.16 to 1.33  ±  0.15, while the SUVmean 
decreased from 0.78 ±  0.12 to 0.63 ±  0.08. When con-
sidering treated and control mice separately at day 0, no 
significant intergroup differences were detected for any 
parameter. However, decreased SUVmax were found for 
the treated group but did not reach statistical signifi-
cance (Z =  1.6, p =  0.1), declining from 1.67 ±  0.15 to 
1.33 ± 0.15.
18F‑FCH PET/CT
Figure 2 displays the MIP for a mouse imaged using 18F-
FCH. In carcinoma tissue, there was a heterogeneous 
uptake of radiolabelled choline, which reflects the het-
erogeneous tumour texture of this model. After treat-
ment, no significant changes were found in the SUVmean 
associated to the tumour or the tumour-to-muscle ratio 
in any group (treated and control).
DCE‑US
The parametric maps derived from DCE-US for a control 
and a treated tumour on the same mouse are displayed in 
Fig. 3 at day 0 and day 3, respectively. According to the 
means, medians, first and third quartiles, no significant 
longitudinal changes were detected in the microvascular 
parameters for any of the experimental groups.
Significant differences were observed between treated 
and control mice at day 3. In the 18F-FCH experimental 
group, the kurtosis of A (Z  =  2, p  <  0.05) was signifi-
cantly decreased in the control group as compared to 
the treated one. In the 18F-FMISO group, differences did 
not reach statistical significance although a clear trend 
was observed. The kurtosis of Akep (Z =  1.7, p =  0.09) 
was increased for the treated group as compared to the 
control group, while the third quartile of the A (Z = 1.7, 
p = 0.09) was declined for the treated group.
The analysis of the median curves revealed longitudi-
nal changes in kel for the treated mice in the 18F-FMISO 
group (Z = 1.9, p < 0.05).
Page 5 of 10Arteaga‑Marrero et al. J Transl Med  (2015) 13:383 
Fig. 1 Maximum intensity projections (MIP) for a mouse with a bilateral tumour imaged using 18F‑FMISO at day 0 (a1, a2) and day 3 (b1, b2). The 
treated (T) and untreated control (C) tumour have been indicated in each image. The colour scale goes from black (no tracer uptake) to red (maxi‑
mum tracer uptake). The green colour indicates intermediate tracer uptake. Scale window is similar in both conditions
Fig. 2 Maximum intensity projections (MIP) for a mouse with a bilateral tumour imaged using 18F‑FCH at day 0 (a1, a2) and day 3 (b1, b2). The 
treated (T) and untreated control (c) tumour have been indicated in each image. The colour scale goes from black (no tracer uptake) to red (maxi‑
mum tracer uptake). The green colour indicates intermediate tracer uptake. Scale window is similar in both conditions
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Correlation to MVD and necrosis
18F‑FMISO PET/CT
A strong negative correlation was found for the treated 
group between MVD assessed automatically and the 
SUVmean of the tumour-to-muscle ratio for the treated 
group (rτ  =  −0.9, p  <  0.05) as displayed in Fig.  4. The 
analysis of the median curves showed a strong negative 
correlation between the MVD assessed manually and the 
kel parameter for the control group at day 3 (rτ = −0.9, 
p < 0.05).
Manual quantification of necrosis correlated strongly to 
the first quartile of kel (rτ = −0.8, p < 0.05) for the treated 
group as can be observed in Fig. 5a. In addition, a corre-
lation was found between the automatic quantification of 
necrosis and the median values of A for the treated group 
(rτ = −0.8, p < 0.05) as can be seen in Fig. 5b. Manual quan-
tification of necrosis was correlated to the SUVmean of the 
tumour-to-muscle ratio for 18F-FMISO PET/CT, although 
it was not statistically significant (rτ = 0.8, p = 0.07).
18F‑FCH PET/CT
No correlation to MVD or necrosis was found for 
the microvascular parameters derived from DCE-US 
Fig. 3 DCE‑US analysis of a mouse on the 18F‑FMISO group showing the control (panel I) and the treated (panel II) tumours at day 0 (upper row) and 
at day 3 (lower row). B‑mode images (a, f) as well as the derived parametric maps are displayed: A (b, g), kep (c, h), kel (d, i), Akep (e, j), respectively
Fig. 4 Relationship between the SUVmean of the tumour‑to‑tissue 
ratio linked to 18F‑ FMISO PET/CT and the microvessel density for 
the control (bold line) and treated (dashed line) groups at day 3. Each 
data point corresponds to the mean ± standard deviation for each 
tumour and the correlation is based on these mean values from each 
experiment
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according to the voxelwise and median analysis. Simi-
larly, no correlation was detected for the functional 
parameters derived from 18F-FCH PET/CT.
In order to discard changes related to differences in 
tumour size, intra- and intergroup variations in microves-
sel density and necrosis were assessed. No significant 
intergroup differences were detected in the histological 
parameters as evaluated manually or automatically. Simi-
larly, no significant differences were detected between 
treated and control groups.
Correlation between PET/CT and DCE-US
18F‑FMISO PET/CT
At day 0, the kurtosis of A was associated to the 
SUVmean in the muscle tissue for the control group 
(rτ = −1, p < 0.05). At day 3, the first quartile of kel was 
negatively correlated to the SUVmean of the tumour-to-
muscle ratio for the treated group (rτ = −0.8, p < 0.05) as 
can be seen in Fig. 6. A negative correlation was observed 
between the first quartile of A and the intensity variation 
derived from PET for the control group, although it was 
not statistically significant (rτ = −0.9, p = 0.09).
18F‑FCH PET/CT
At day 0, no correlation was found between the 
SUVmean of the tumour-to-muscle ratio for 18F-FCH 
and the microvascular parameters evaluated by DCE-US.
At day 3, a negative correlation was found between the 
homogeneity of the SUVmean for 18F-FCH PET and the 
first quartile of kep derived from DCE-US in the treated 
group, without reaching statistical significance (rτ = −1, 
p = 0.09).
Discussion
In the present study functional multimodal imaging was 
used to assess early response to radiation treatment in a 
prostate tumour xenograft. Longitudinal changes were 
only found for 18F-FMISO PET/CT, which showed lower 
maximum uptake (SUVmax) and SUVmean in irradiated 
tumours, suggesting a decrease in hypoxia. The SUVmax 
Fig. 5 Relationship observed in the 18F‑FMISO PET/CT group at day 3 between necrosis and a the mean values of kel derived from DCE‑US as well 
as to b the mean values of A for the control (bold line) and treated (dashed line) mice. Each data point corresponds to the mean ± standard devia‑
tion for each tumour and the correlation is based on these mean values from each experiment
Fig. 6 Correlation observed at day 3 between the SUVmean of the 
tumour‑to‑tissue ratio linked to 18F‑FMISO PET/CT and kel for the 
control (bold line) and treated (dashed line) groups. Each data point 
corresponds to the mean ± standard deviation for each tumour and 
the correlation is based on these mean values from each experiment
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has been shown to predict cancer prognosis [6]. Local 
recurrence and distant metastasis frequently occur after 
radiation therapy and these are caused, at least in part, by 
hypoxia [19]. Diminished blood perfusion and hypoxia in 
tumours results from abnormal structure [20]. The distri-
bution of oxygen from tumour blood vessels to hypoxic 
tumour cells is dramatically improved after radiother-
apy as a result of the death of well-oxygenated tumour 
cells and a subsequent decrease in oxygen consump-
tion in cells close to vessels [19]. 18F-FMISO is linked to 
hypoxia which confers resistance to radiation through 
the hypoxia-inducible factor 1 (HIF-1), and therefore 
correlates with a poor prognosis [1, 20]. The same trend 
towards lower 18F-FMISO uptake has been reported in 
bevacizumab treated tumours of the human colon can-
cer cell line LS174T [5]. Actually, bevacizumab increased 
hypoxia in the tumour but this could not be detected by 
18F-FMISO PET or pimonidazole staining. It was con-
cluded that the distribution of the tracer was hampered 
by the effects of bevacizumab on vascular permeability 
and perfusion. However, tumours treated with Avastin 
(bevacizumab) had increased uptake of 18F-FMISO and 
reduced blood flow and vessel permeability [21].
For 18F-FCH PET, larger changes were expected in 
the tumour tissue as cell death of viable, normoxic cells 
caused by radiotherapy reduce the uptake of 18F-FCH, 
which is related to cell growth. 18F-FCH primary sites of 
uptake are kidney and liver, and normal distribution of 
18F-FCH is in the salivary glands, liver, spleen, and pan-
creas; with variable activity in the bowel, in addition to 
the uptake in the kidneys and bladder from excretion [3]. 
In this study, heterogeneous uptake of labelled choline in 
carcinoma tissue has been detected, which depends on 
choline kinase overexpressed in tumour subregions [22]. 
A reduced tracer uptake of 18F-FCH has been reported 
in hypoxic conditions [4], and hypoxia was more pro-
found in pre-treatment conditions as demonstrated in 
this study using the hypoxia tracer. Hypoxic tumours 
may exhibit low uptake of choline due to poor perfu-
sion as previously suggested or that tumour hypoxia may 
notably lower choline metabolic trapping in cancer cells. 
Thus choline tracer retention may be related to tumour 
oxygenation status though effects on choline kinase 
activity [7]. Furthermore, a decrease in choline uptake 
was reported in response to hypoxia, which was mark-
edly declined upon androgen depletion in androgen-sen-
sitive prostate cancer cells [1]. Similarly, a small decrease 
in 11C-choline uptake was reported for the CWR22 
tumour model after castration [23]. The reduced uptake 
of radiolabelled choline and choline derivatives in small-
rodent prostate tumour models was attributed to an 
excess of the nonlabelled precursor dimethylaminoetha-
nol [23].
In this study significant correlations between tech-
niques as well as to histological parameters have been 
detected. For the 18F-FMISO group, the SUVmean of 
the tumour-to-muscle ratio was negatively correlated 
to MVD for the treated group, while the correlation to 
necrosis was not statistically significant. Furthermore, 
the microvascular parameter kel was found negatively 
correlated to the SUVmean of the tumour-to-muscle 
ratio, necrosis, and MVD. Tumour heterogeneity has 
been included in the study by using the descriptive 
analysis of the histograms associated to PET/CT and 
DCE-US. Imbalance between oxygen supply and con-
sumption in a malignant solid tumour is a major cause 
of heterogeneity [19]. Kurtosis, skewness, percentiles and 
their changes have been shown to be quantitative mark-
ers of tumour heterogeneity with a direct correlation to 
the underlying structural, physiological, molecular and 
metabolic changes [24]. The kurtosis, homogeneity and 
intensity variation derived from PET/CT, were related 
to the microvascular parameters derived from DCE-US. 
Particularly, correlations to the microvascular parameter 
A and kurtosis were observed pre-treatment or for the 
control group, whereas correlation to intensity variation 
was related to the treated group. A lesser degree of spa-
tial heterogeneity in hypoxia may be associated to a more 
localized and well-demarcated process, for instance the 
gradient in vascularization, which decreases towards the 
centre of the tumour. In contrast a diffuse hypoxic pro-
cess indicates a response to hypoxic stress with associ-
ated biological changes [25].
The reduced number of mice in the 18F-FCH PET/
CT group may have prevented the observation of addi-
tional correlations between metabolic and microvascular 
parameters. Nevertheless, a strong relationship to kurto-
sis was found for the amplitude of the contrast uptake A 
that was not related to the treatment. The treated group 
exhibit a negative relationship between homogeneity and 
kep that did not reach statistical significance (data not 
shown). Kinetic analysis of dynamic 18F-FDG using the 
same tumour model, reported heterogeneous intragroup 
parameters variation 24 h after radiation treatment with 
7.5 Gy in contrast to the homogeneous distribution pre-
sented in the control group [26]. In addition, radiation 
treatment increases permeability facilitating the diffu-
sion of injected substances into the EES [27]. Clinically, 
the value of 18F-FCH PET in the stage of prostate cancer 
is controversial and highly variable [3]. The common sex-
tant biopsy method is prone to sampling errors, however, 
prostate sextants with malignant involvement demon-
strated stable or increasing 18F-FCH uptake over time 
while most benign tissue demonstrated a corresponding 
decrease [28]. These observations are in correspond-
ence with our results. In addition, correlation between 
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SUVmax and sextants with maximal tumour infiltration 
has been reported, as well as a significant difference in 
SUVmax between malignant and benign regions [28, 29].
Earlier, 24  h after treatment with a single dose 
of 7.5  Gy, we detected longitudinal changes in the 
microvascular parameter kel derived from DCE-US as 
assessed by the median values [15]. In addition, MVD 
and necrosis were correlated to kep for the treated 
group only in high intensity areas of enhancement. In 
the present study, 48 h after a dose of 10 Gy, we identi-
fied longitudinal changes for kel only in the analysis of 
the median curves and exclusively for the 18F-FMISO 
group. In addition, necrosis was negatively corre-
lated to A and kel for the treated group, whereas kel 
was linked to MVD for the control group. Thus, kel 
could indicate the tumour blood supply and vascu-
lar integrity. We associate the differences observed, in 
comparison to the earlier study, to the increased time 
post-treatment and the increased radiation dose. These 
two factors affect the window of normalization which 
occurs after treatment regarding the destruction of 
vessels. Intratumour HIF-1 activity has been shown to 
reach a minimum level at an early phase and subse-
quently increase to a plateau in a late phase. The timing 
and duration of the activation was shown to be depend-
ent on the dose of radiation [19]. Radiation treatment 
has a better outcome when given during the normali-
zation window in which the perfusion is improved and 
the hypoxia reduced due to direct damage or killing 
of well-oxygenated tumour endothelial cells and the 
subsequent decrease in oxygen consumption (tumour 
reoxygenation) [19, 20, 30, 31].
However, a different normalization window does not 
explain the lack of correlation between the histopatholog-
ical findings and the microvascular parameters generated 
from DCE-US for the 18F-FCH group. The estimation of 
the microvascular parameters kep and kel derived from 
DCE-US in the 18F-FMISO and the 18F-FCH group dif-
fered significantly between the median and the voxelwise 
analysis pre-treatment. The same effect was noticed post-
treatment for the control group but not for the treated 
one (data not shown). A small sample size may have had 
an impact on the estimation of the microvascular param-
eters, and therefore, failed to show clearly the effects of 
the treatment. However, we cannot discard other factors 
associated to the experimental conditions.
Conclusions
The multimodal approach 18F-FMISO PET/CT and DCE-
US seems to provide reliable, non-invasive biomarkers in 
the assessment of both microvasculature and necrosis as 
validated by histology. Particularly, the SUVmean of the 
tumour-to-muscle ratio derived from 18F-FMISO PET/
CT is negatively correlated to MVD and positively linked 
to necrosis. kel derived from DCE-US present promising 
capabilities as a suitable imaging biomarker for radia-
tion treatment monitoring since it is negatively linked 
to necrosis and MVD. Moreover, this parameter cor-
relates to the SUVmean of the tumour-to-muscle ratio 
derived from 18F-FMISO PET/CT. This is of importance 
considering that the combination of information from 
multimodal approaches will improve the sensitivity and 
specificity of the diagnostic process.
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